Hand (New York, N.Y.) · 2026
Comparison of Clinical and Electrophysiological Outcomes of Local Versus Intramuscular Steroid in Mild-to-Moderate Carpal Tunnel Syndrome: An Open-Label, Blinded Endpoint Randomized Clinical Trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kumar Mritunjai, Yende Niket, Singh Rajni, Tiwari Ashutosh, Kumar Niraj
Аннотация
BACKGROUND: In view of paucity of studies, this study compared the effects of local versus intramuscular corticosteroid injections on clinical outcomes and electrophysiological parameters in patients with mild-to-moderate carpal tunnel syndrome (CTS).
METHODS: This study enrolled 190 CTS patients between October 2023 to March 2025. Participants were randomized to receive either a single local injection of 40 mg methylprednisolone (MP) with 0.5 mL lidocaine at the wrist (local corticosteroid injection [LCI] arm) or a single 40 mg intramuscular (IM) MP injection in the deltoid (IM arm). The primary outcome was the Symptom Severity Scale (SSS) score at 3 months. Secondary outcomes included SSS at 1 month, Functional Status Scale (FSS), and median nerve electrophysiological changes at 1 and 3 months. Significant clinical response was defined as a reduction of ≥0.8 points in SSS or ≥0.5 in FSS.
RESULTS: Follow-up data were missing for 29 patients at 3 months. At 3 months, mean SSS score was 1.51 (SD 0.58) in LCI and 1.64 (SD 0.72) in IM arm (P = .21). However, the LCI arm showed significantly greater reduction in SSS/FSS scores at 1 month. Considering patients lost to follow-up as treatment failures, response rate at 3 months was 70.5% in LCI and 72.6% in IM arm (P = .75). Median nerve conduction results were comparable, although the LCI arm showed greater improvement at 3 months from baseline.
CONCLUSIONS: In patients with mild-to-moderate CTS, LCI resulted in greater reduction in Boston Carpal Tunnel Questionnaire scores and in median nerve conductions at 1 month. However, outcome at 3 months was similar.
METHODS: This study enrolled 190 CTS patients between October 2023 to March 2025. Participants were randomized to receive either a single local injection of 40 mg methylprednisolone (MP) with 0.5 mL lidocaine at the wrist (local corticosteroid injection [LCI] arm) or a single 40 mg intramuscular (IM) MP injection in the deltoid (IM arm). The primary outcome was the Symptom Severity Scale (SSS) score at 3 months. Secondary outcomes included SSS at 1 month, Functional Status Scale (FSS), and median nerve electrophysiological changes at 1 and 3 months. Significant clinical response was defined as a reduction of ≥0.8 points in SSS or ≥0.5 in FSS.
RESULTS: Follow-up data were missing for 29 patients at 3 months. At 3 months, mean SSS score was 1.51 (SD 0.58) in LCI and 1.64 (SD 0.72) in IM arm (P = .21). However, the LCI arm showed significantly greater reduction in SSS/FSS scores at 1 month. Considering patients lost to follow-up as treatment failures, response rate at 3 months was 70.5% in LCI and 72.6% in IM arm (P = .75). Median nerve conduction results were comparable, although the LCI arm showed greater improvement at 3 months from baseline.
CONCLUSIONS: In patients with mild-to-moderate CTS, LCI resulted in greater reduction in Boston Carpal Tunnel Questionnaire scores and in median nerve conductions at 1 month. However, outcome at 3 months was similar.